2026 SFDA Roadmap: Mastering Pharmaceutical Registration in Saudi Arabia

In this episode of the DDReg Knowledge Capsule, we explore the regulatory complexities of entering the Middle East’s largest pharmaceutical market, currently valued between $10.5 and $12.3 billion. We break down the SFDA’s comprehensive registration process, from the mandatory appointment of a Saudi Authorized Representative (SAR) to the technical nuances of submitting eCTD-compliant dossiers.The discussion highlights critical compliance hurdles, such as the strict requirements for Arabic labeling and the necessity of providing stability data tailored to Zone IVb climatic conditions.We also cover the typical 8 to 18-month approval timeline and the vital post-approval obligations—including pharmacovigilance and five-year renewals—required to maintain market access.This session is designed to help manufacturers transform the registration process from a bureaucratic hurdle into a strategic success